Max Healthcare Institute Limited has informed the Exchange about Copy of Newspaper Publication for standalone and consolidated financial results for the quarter ended June 30, 2025
MAXHEALTH · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Max Healthcare reported its Q1 FY26 (quarter ended June 30, 2025) results, with consolidated revenue from operations rising about 31% year-on-year to ₹2,027.57 crore (₹1,542.95 crore in Q1 FY25). Profit after tax grew roughly 30% YoY to ₹307.97 crore, with basic EPS of ₹3.17 (vs ₹2.17 in Q1 FY25). Standalone revenue stood at ₹694.02 crore with a PAT of ₹166.03 crore. The results were approved by the Board on August 13, 2025, and are unmodified by statutory auditors S.R. Batliboi & Co. LLP. The company also announced two expansion moves: a ₹120 crore land acquisition in Ghaziabad to add ~150 beds at Max Super Specialty Hospital, Vaishali, and a new 130-bed hospital in Dehradun focused on oncology, expected by 2028.
Strong double-digit YoY growth in both revenue and profit signals healthy operational momentum, which is positive for shareholders. Capacity expansion through the Ghaziabad land deal and the new Dehradun hospital should support future revenue growth, though the Dehradun facility is a 2–3 year project. Overall, the filing is constructive for the stock.